Author of

• 18973

  +

  P2.01 - Advanced NSCLC (ID 618)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)

  • 24615

    +

    P2.01-075b - Analysis of the Safety and Usefulness of Nab-Paclitaxel Therapy in Patients with Non-Small Cell Carcinoma (ID 8089)

    09:00 - 09:00  |  Presenting Author(s): I. Eriko
    • Abstract

    Background:
    Nab-paclitaxel (nab-PTX) is used as primary therapy in the treatment of non-small cell carcinoma. However, we frequently use it as secondary or later therapy, or for patients with performance status (PS) of >=2. Therefore, we analyzed the response to and safety of nab-PTX therapy in the treatment for patients with non-small cell carcinoma in our hospital.
    
    Method:
    Between January 2014 and March 2017, 46 patients received chemotherapy with nab-PTX, or nab-PTX and carboplatin for non-small cell carcinoma in our hospital. We used the standard nab-PTX 100 mg/m[2] and carboplatin AUC5, except in older patients and those with PS of >=2, for whom we reduced the medication dose.
    
    Result:
    The median age of the patients was 66 years (range, 26–78 years), and 17 patients were older than 75 years. Of the patients, 39 were male and 7 were female, and 41 patients were smokers. Ten patients had preexisting pulmonary fibrosis, and 30 had preexisting emphysema. The tissue types of the tumors were squamous cell carcinoma, adenocarcinoma, other types, and not diagnosed in 32, 10, 2, and 2 of the patients, respectively. The PS of 7, 33, and 6 patients before treatment were 0, 1, and 2, respectively. The tumor stage was ⅡB, ⅢA, ⅢB, ⅣA, ⅣB, and postoperative recurrence was observed in 3, 4, 11, 15, 9, and 4 cases, respectively. The treatments were used as primary, secondary, or third or later therapy in 8, 25, and 13 patients, respectively. Twenty-five patients received the combination therapy. The median follow-up period was 8.5 months. The response rate (RR) was 11%. The disease control rate (DCR) was 20%. The median progression-free survival (PFS) was 3 months. Twenty patients experienced adverse events of grade 3 or higher. These events included leukocytopenia (14, 70%), anemia (3, 15%), anorexia (3, 15%), febrile neutropenia (3, 15%), fatigue (1, 5%), and thrombopenia (1, 5%). In addition, the data of the patients treated with nab-PTX as secondary or later therapy indicated a RR of 13%, DCR of 18%, and median PFS of 3 months. The data of the patients with PS of >=2 indicated a RR of 0%, DCR of 16.7%, and PFS of 1.5 months.
    
    Conclusion:
    Nab-PTX is used as secondary or later therapy in patients with non-small cell carcinoma and PS of >=2. Nab-PTX therapy is useful and safe at a constant rate. We will analyze more cases, including patients under observation, and will report the data during the presentation.